SOLIRIS (eculizumab): The first treatment specifically approved for PNH

SOLIRIS OneSource Patient Materials

OneSource Materials

The following resources are available that contain information regarding the OneSource™ program. Sign up to receive this information, and keep informed on the latest news in PNH, SOLIRIS® (eculizumab), and the OneSource Program.

OneSource MaterialsTo become enrolled in the OneSource program:

  1. Call OneSource at 1.888.SOLIRIS (1.888.765.4747) to speak to an Alexion Case Manager
     
  2. The Alexion Case Manager will collect information and explain the OneSource services to you
     
  3. You will need to sign and return the Alexion consent forms to OneSource (these can be mailed or faxed back to 1.203.699.2000)
     
  4. The Alexion Case Manager is now in a position to help you navigate insurance issues and coordinate other needs that are important to your SOLIRIS treatment plan

Please call 1.888.SOLIRIS (1.888.765.4747) to learn more about OneSource.

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Patients should be vaccinated with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS. Revaccinate according to current medical guidelines for vaccine use.

Patients should be monitored closely for early signs of meningococcal infections and evaluated immediately if infection is suspected, and treated with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.